For Q3 FY2025 (ended September 30, 2025), Allogene Therapeutics reported no revenue. Net loss was $42.6 million for the three months ended March 31, 2026, improving 28.7% year-over-year. Operating loss was $46.1 million, improving 29.3% year-over-year. Diluted EPS was -$0.18, improving 35.7% year-over-year.
•No revenue reported for Q3 FY2025.
•Net loss of $42.6 million improved 28.7% year-over-year.
•Operating loss of $46.1 million improved 29.3% year-over-year.
•Diluted EPS of -$0.18 improved 35.7% year-over-year.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.
It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies.
The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL).
Additionally, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC) ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). Incorporated in 2017, the company is headquartered in South San Francisco, California.
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing and commercializing genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. The company uses protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies to create a pipeline of multiple allogeneic CAR T cell product candidates. Its lead candidate, cemacabtagene ansegedleucel (cema-cel), targets CD19 for large B-cell lymphoma (LBCL). Other candidates include ALLO-316, targeting CD70 for renal cell carcinoma (RCC), and ALLO-329, targeting both CD19 and CD70 for autoimmune diseases such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc).
Where is Allogene Therapeutics (ALLO) listed and what currency does it trade in?
Allogene Therapeutics is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol ALLO. Its shares trade in United States Dollars (USD), which is the official currency of the United States. The company is headquartered in South San Francisco, California, and operates primarily in the U.S. market.
What sector and industry does Allogene Therapeutics (ALLO) belong to?
Allogene Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on developing innovative therapies using living cells, particularly allogeneic (donor-derived) CAR T cells, to treat serious diseases like cancer and autoimmune conditions. This industry is characterized by high research and development costs, regulatory hurdles, and the potential for breakthrough treatments.
Where is Allogene Therapeutics (ALLO) headquartered and what markets does it serve?
Allogene Therapeutics is headquartered in South San Francisco, California, United States. The company serves the global market for cancer and autoimmune disease treatments, with a primary focus on the United States. Its clinical trials and development programs target patients with large B-cell lymphoma, renal cell carcinoma, and autoimmune diseases such as systemic lupus erythematosus, idiopathic inflammatory myopathies, and systemic sclerosis.
What are the main product candidates in Allogene Therapeutics' (ALLO) pipeline?
Allogene Therapeutics has a pipeline of allogeneic CAR T cell product candidates. The most advanced is cemacabtagene ansegedleucel (cema-cel), which targets CD19 for the treatment of large B-cell lymphoma (LBCL). Another candidate, ALLO-316, targets CD70 for renal cell carcinoma (RCC). Additionally, ALLO-329 is an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for autoimmune diseases (AID), including systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). These candidates leverage protein engineering, gene editing, and gene insertion technologies.